Small Cell Lung Cancer
Conditions
Brief summary
This pilot research trial studies molecular signatures of the return of cancer after a period of improvement (relapse) in tissue samples from patients with small cell lung cancer who are receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from patients with small cell lung cancer in the laboratory may help doctors learn more about the changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer relapse.
Detailed description
PRIMARY OBJECTIVES: I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA) from 3 human patients before and after relapse to identify the molecular signatures of relapse. OUTLINE: Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
Interventions
OTHERcytology specimen collection procedure
Correlative studies
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
University of Southern California
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any patient seen at Norris or County with histologically confirmed SCLC, with tissue in the Norris Cancer Center Tumor Repository * Patients must be undergoing or about to start first line treatment with cisplatin and etoposide * Patients may not have a second malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in tumor tissue molecular profiles | Baseline to up to 1 year | Profiles of pre- and post-relapse tumor tissue will be compared. Data will be compared with mouse data and overlaps determined. |
Countries
United States
Outcome results
None listed